+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Actinic (Solar) Keratosis - Pipeline Review, H1 2020

  • ID: 5017414
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 66 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Athenex Inc
  • G&E Corp
  • MedC Biopharma Ltd
  • Nanology LLC
  • Neonc Technologies Inc
  • Singh Biotechnology LLC
  • MORE
Actinic (Solar) Keratosis - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Actinic (Solar) Keratosis - Pipeline Review, H1 2020, provides an overview of the Actinic (Solar) Keratosis (Dermatology) pipeline landscape.

An actinic keratosis, also known as a solar keratosis, is a scaly or crusty growth (lesion). It most often appears on the bald scalp, face, ears, lips, backs of the hands and forearms, shoulders, neck or any other areas of the body frequently exposed to the sun. The signs and symptoms of an actinic keratosis include a hard, wart-like surface, patch or bump on the top layer of skin, itching or burning in the affected area and color as varied as pink, red or brown, or flesh-colored. The predisposing factors include age, sunny climate, history of frequent or intense sun exposure or sunburn, pale skin, red or blond hair, and blue or light-colored eyes and a weak immune system as a result of chemotherapy, chronic leukemia, AIDS or organ transplant medications.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Actinic (Solar) Keratosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Actinic (Solar) Keratosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Unknown stages are 1, 1, 5, 3 and 1 respectively.

Actinic (Solar) Keratosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Actinic (Solar) Keratosis (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Actinic (Solar) Keratosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Actinic (Solar) Keratosis (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Athenex Inc
  • G&E Corp
  • MedC Biopharma Ltd
  • Nanology LLC
  • Neonc Technologies Inc
  • Singh Biotechnology LLC
  • MORE
  • Introduction
  • Report Coverage
  • Actinic (Solar) Keratosis - Overview
  • Actinic (Solar) Keratosis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Actinic (Solar) Keratosis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Actinic (Solar) Keratosis - Companies Involved in Therapeutics Development
  • AmDerma Pharmaceuticals LLC
  • Athenex Inc
  • G&E Corp
  • Henderson Morley Plc (Inactive)
  • Laboratories Ojer Pharma SL
  • MedC Biopharma Ltd
  • Nanology LLC
  • Neonc Technologies Inc
  • Oncology Research International Ltd
  • Singh Biotechnology LLC
  • Vidac Pharma Ltd
  • Actinic (Solar) Keratosis - Drug Profiles
  • (digoxin + furosemide) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AM-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • imiquimod SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MDC-2040 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NEO-412 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ORIL-007 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SBT-300 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SOR-007 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SRT-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tirbanibulin mesylate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tuvatexib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Actinic (Solar) Keratosis - Dormant Projects
  • Actinic (Solar) Keratosis - Discontinued Products
  • Actinic (Solar) Keratosis - Product Development Milestones
  • Featured News & Press Releases
  • Mar 09, 2020: Athenex announces FDA acceptance for filing of U.S. NDA for tirbanibulin ointment in actinic keratosis
  • Mar 02, 2020: Athenex’s partner Almirall announces EMA acceptance for filing of Marketing Authorization Application (MAA) for tirbanibulin ointment in actinic keratosis
  • Oct 28, 2019: Athenex announces progress update from partner Almirall on Tirbanibulin Ointment
  • Mar 04, 2019: Athenex announces positive topline results from two phase III studies of KX2-391 ointment 1% featured in late breaker program at the 2019 American Academy of Dermatology Annual Meeting
  • Feb 25, 2019: Athenex to host conference call with key opinion leader following oral presentation of phase III results of KX2-391 ointment in the treatment of actinic keratosis at the American Academy of Dermatology Annual Meeting
  • Feb 04, 2019: Athenex announces late-breaking oral presentation of KX2-391 ointment in two phase III studies at the American Academy of Dermatology Annual Meeting
  • Dec 16, 2018: Vidac Pharma announce publication of peer reviewed article on VDA-1102 mechanism of action
  • Sep 18, 2018: DFB Soria completes a phase 2 clinical Trial of submicron particle Paclitaxel anhydrous ointment for actinic keratosis
  • Jul 26, 2018: Almirall announces that both phase III trials of KX2-391 for actinic keratosis achieved primary endpoint
  • Jul 26, 2018: Athenex Announces That Two Phase 3 Pivotal Efficacy Studies of KX2-391 in Actinic Keratosis Achieved Their Primary Endpoints
  • Jul 10, 2018: Vidac Pharma Announces Initiation of Phase 2b Clinical Trial of VDA-1102 Ointment in Patients with Actinic Keratosis
  • Feb 20, 2018: Athenex Announces Phase II Clinical Study Results for KX2-391 Ointment for the Treatment of Actinic Keratosis in the American Academy of Dermatology Meeting
  • Feb 14, 2018: Athenex Announces Early Completion of Patients Enrollment for Two Phase III Clinical Studies of KX2-391 Ointment for Actinic Keratosis
  • Dec 18, 2017: NanOlogy Announces First Patient Enrolled in a Pancreatic Cancer Phase II Clinical Trial of NanoPac Adding to Trials in Prostate and Ovarian Cancers
  • Nov 28, 2017: Athenex Announces Acceptance of Phase II Data of KX2-391 for the Treatment of Actinic Keratosis for Presentation at the American Academy of Dermatology Meeting
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Actinic (Solar) Keratosis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Actinic (Solar) Keratosis - Pipeline by AmDerma Pharmaceuticals LLC, H1 2020
  • Actinic (Solar) Keratosis - Pipeline by Athenex Inc, H1 2020
  • Actinic (Solar) Keratosis - Pipeline by G&E Corp, H1 2020
  • Actinic (Solar) Keratosis - Pipeline by Henderson Morley Plc (Inactive), H1 2020
  • Actinic (Solar) Keratosis - Pipeline by Laboratories Ojer Pharma SL, H1 2020
  • Actinic (Solar) Keratosis - Pipeline by MedC Biopharma Ltd, H1 2020
  • Actinic (Solar) Keratosis - Pipeline by Nanology LLC, H1 2020
  • Actinic (Solar) Keratosis - Pipeline by Neonc Technologies Inc, H1 2020
  • Actinic (Solar) Keratosis - Pipeline by Oncology Research International Ltd, H1 2020
  • Actinic (Solar) Keratosis - Pipeline by Singh Biotechnology LLC, H1 2020
  • Actinic (Solar) Keratosis - Pipeline by Vidac Pharma Ltd, H1 2020
  • Actinic (Solar) Keratosis - Dormant Projects, H1 2020
  • Actinic (Solar) Keratosis - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Actinic (Solar) Keratosis - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Actinic (Solar) Keratosis - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Actinic (Solar) Keratosis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AmDerma Pharmaceuticals LLC
  • Athenex Inc
  • G&E Corp
  • Henderson Morley Plc (Inactive)
  • Laboratories Ojer Pharma SL
  • MedC Biopharma Ltd
  • Nanology LLC
  • Neonc Technologies Inc
  • Oncology Research International Ltd
  • Singh Biotechnology LLC
  • Vidac Pharma Ltd
Note: Product cover images may vary from those shown
Adroll
adroll